An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design.
Califf
Robert M
RM
Lokhnygina
Yuliya
Y
Cannon
Christopher P
CP
Stepanavage
Michael E
ME
McCabe
Carolyn H
CH
Musliner
Thomas A
TA
Pasternak
Richard C
RC
Blazing
Michael A
MA
Giugliano
Robert P
RP
Harrington
Robert A
RA
Braunwald
Eugene
E
D054058:Acute Coronary Syndrome / Q000097:blood / Q000188:drug therapy*; D001384:Azetidines / Q000627:therapeutic use*; D008078:Cholesterol, LDL / Q000097:blood; D004338:Drug Combinations; D000069499:Ezetimibe, Simvastatin Drug Combination; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D015233:Models, Statistical; D010349:Patient Compliance; D012107:Research Design; D019821:Simvastatin / Q000627:therapeutic use*; D016896:Treatment Outcome
D001384:Azetidines; D008078:Cholesterol, LDL; D004338:Drug Combinations; D000069499:Ezetimibe, Simvastatin Drug Combination; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D019821:Simvastatin